Goldman Sachs Initiates Coverage On NewAmsterdam Pharma Co with Neutral Rating, Announces Price Target of $27
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Goldman Sachs analyst Asad Haider initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Neutral rating and announces Price Target of $27.
Goldman Sachs analyst Asad Haider initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Neutral rating and announces Price Target of $27.